Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 1/2018

01-01-2018 | Editorial

The importance of a well-structured pancreatic screening program for familial and hereditary pancreatic cancer

Author: Hans F. A. Vasen

Published in: Familial Cancer | Issue 1/2018

Login to get access

Excerpt

In this issue of Familial Cancer, Barnes et al. describe a screening program for individuals at high risk of developing pancreatic ductal adenocarcinoma (PDAC) [1]. Approximately 3–10% of all patients with PDAC have a positive family history for this cancer [2], and 4% have an underlying gene defect, with ATM, BRCA1 & BRCA2, and PALB2 being the most commonly effected genes [3‐6] (Table 1). Familial pancreatic cancer (FPC) is defined by the occurrence of PDAC in two or more first-degree relatives, in the absence of an underlying gene defect [2]. The risk of developing PDAC depends on the particular gene defect (Table 1) [7‐12], and in FPC, on the number of first-degree family members with PDAC. …
Literature
1.
2.
Bartsch DK, Gress TM, Langer P (2012) Familial pancreatic cancer—current knowledge. Nat Rev Gastroenterol Hepatol 9(8):445–453CrossRefPubMed
3.
Shindo K, Yu J, Suenaga M, Fesharakizadeh S, Cho C, Macgregor-Das A et al (2017) Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol 35(30):3382–3390CrossRefPubMed
4.
Zhen DB, Rabe KG, Gallinger S, Syngal S, Schwartz AG, Goggins MG et al (2015) BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med 17(7):569–577CrossRefPubMed
5.
Roberts NJ, Norris AL, Petersen GM, Bondy ML, Brand R, Gallinger S et al (2016) Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov 6(2):166–175CrossRefPubMed
6.
7.
de Snoo FA, Bishop DT, Bergman W, van Leeuwen I, van der Drift C, van Nieuwpoort FA et al (2008) Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res 14(21):7151–7157CrossRefPubMed
8.
Thompson D, Easton DF, Breast Cancer Linkage C (2002) Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94(18):1358–1365CrossRefPubMed
9.
van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HF et al (2005) Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 42(9):711–719CrossRefPubMedPubMedCentral
10.
11.
Breast Cancer Linkage C (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91(15):1310–1316CrossRef
12.
Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthai E, Carrato A et al (2016) Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three european expert centers. J Clin Oncol 34(17):2010–2019CrossRefPubMed
13.
Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB (1999) Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 131(4):247–255CrossRefPubMed
14.
Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z et al (2012) Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142(4):796–804 (quiz e14-5)CrossRefPubMedPubMedCentral
15.
Langer P, Kann PH, Fendrich V, Habbe N, Schneider M, Sina M et al (2009) Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 58(10):1410–1418CrossRefPubMed
16.
Al-Sukhni W, Borgida A, Rothenmund H, Holter S, Semotiuk K, Grant R et al (2012) Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg 16(4):771–783CrossRefPubMed
17.
Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I et al (2013) International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62(3):339–347CrossRefPubMed
18.
Harinck F, Konings IC, Kluijt I, Poley JW, van Hooft JE, van Dullemen HM et al (2016) A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals. Gut 65(9):1505–1513CrossRefPubMed
19.
Pandharipande PV, Jeon A, Heberle CR, Dowling EC, Kong CY, Chung DC et al (2015) Screening for pancreatic adenocarcinoma in BRCA2 mutation carriers: results of a disease simulation model. EBioMedicine 2(12):1980–1986CrossRefPubMedPubMedCentral
Metadata
Title
The importance of a well-structured pancreatic screening program for familial and hereditary pancreatic cancer
Author
Hans F. A. Vasen
Publication date
01-01-2018
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2018
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-017-0066-y

Other articles of this Issue 1/2018

Familial Cancer 1/2018 Go to the issue

Original Article

Next generation sequencing is informing phenotype: a TP53 example

Original Article

A multi-gene panel study in hereditary breast and ovarian cancer in Colombia

Original Article

Constitutional mismatch repair deficiency and Lynch syndrome among consecutive Arab Bedouins with colorectal cancer in Israel

Original Article

Heightened perception of breast cancer risk in young women at risk of familial breast cancer

Short Communication

Contiguous gene deletion of chromosome 2p16.3-p21 as a cause of Lynch syndrome

Short Communication

Early onset renal cell carcinoma in an adolescent girl with germline FLCN exon 5 deletion
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits